Separate terms with OR to return results that match either term.
 
Clear All
10,000 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
Show Entries
NDC-11 (Package) NDC-9 (Product) Generic Name Brand Name Strength SEER*Rx Category Major Class Minor Class (Descending) Administration Route Package Effective Date Package Discontinuation Date Status
61958-1701-01 61958-1701 Idelalisib Zydelig 100.0 mg/1 Chemotherapy Enzyme Inhibitor PI3K Oral July 23, 2014 In Use
61958-1702-01 61958-1702 Idelalisib Zydelig 150.0 mg/1 Chemotherapy Enzyme Inhibitor PI3K Oral July 23, 2014 In Use
73116-0215-28 73116-0215 Duvelisib COPIKTRA 15.0 mg/1 Chemotherapy Enzyme Inhibitor PI3K Oral Sept. 25, 2018 In Use
73116-0215-56 73116-0215 Duvelisib COPIKTRA 15.0 mg/1 Chemotherapy Enzyme Inhibitor PI3K Oral Sept. 25, 2018 In Use
73116-0225-28 73116-0225 Duvelisib COPIKTRA 25.0 mg/1 Chemotherapy Enzyme Inhibitor PI3K Oral Sept. 25, 2018 In Use
73116-0225-56 73116-0225 Duvelisib COPIKTRA 25.0 mg/1 Chemotherapy Enzyme Inhibitor PI3K Oral Sept. 25, 2018 In Use
73116-0115-01 73116-0115 duvelisib COPIKTRA 15.0 mg/1 Chemotherapy Enzyme Inhibitor PI3K Oral Sept. 25, 2018 In Use
73116-0115-02 73116-0115 duvelisib COPIKTRA 15.0 mg/1 Chemotherapy Enzyme Inhibitor PI3K Oral Sept. 25, 2018 In Use
73116-0125-01 73116-0125 duvelisib COPIKTRA 25.0 mg/1 Chemotherapy Enzyme Inhibitor PI3K Oral Sept. 25, 2018 In Use
73116-0125-02 73116-0125 duvelisib COPIKTRA 25.0 mg/1 Chemotherapy Enzyme Inhibitor PI3K Oral Sept. 25, 2018 In Use
00078-0715-02 00078-0715 Alpelisib PIQRAY Chemotherapy Enzyme Inhibitor PI3K Oral May 24, 2019 In Use
00078-0715-91 00078-0715 Alpelisib PIQRAY Chemotherapy Enzyme Inhibitor PI3K Oral May 24, 2019 In Use
50419-0385-01 50419-0385 Copanlisib Aliqopa 15.0 mg/mL Chemotherapy Enzyme Inhibitor PI3K Intravenous Sept. 14, 2017 In Use
50419-0385-72 50419-0385 Copanlisib Aliqopa 15.0 mg/mL Chemotherapy Enzyme Inhibitor PI3K Intravenous Oct. 30, 2018 In Use
71779-0115-01 71779-0115 duvelisib Copiktra 15.0 mg/1 Chemotherapy Enzyme Inhibitor PI3K Oral Sept. 25, 2018 In Use
71779-0115-02 71779-0115 duvelisib Copiktra 15.0 mg/1 Chemotherapy Enzyme Inhibitor PI3K Oral Sept. 25, 2018 In Use
71779-0125-01 71779-0125 duvelisib Copiktra 25.0 mg/1 Chemotherapy Enzyme Inhibitor PI3K Oral Sept. 25, 2018 In Use
71779-0125-02 71779-0125 duvelisib Copiktra 25.0 mg/1 Chemotherapy Enzyme Inhibitor PI3K Oral Sept. 25, 2018 In Use
72064-0110-30 72064-0110 avapritinib Ayvakit 100.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor PDGFR, KIT, CSFR1 Oral Jan. 9, 2020 In Use
72064-0120-30 72064-0120 avapritinib Ayvakit 200.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor PDGFR, KIT, CSFR1 Oral Jan. 9, 2020 In Use
72064-0125-30 72064-0125 avapritinib Ayvakit 25.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor PDGFR, KIT, CSFR1 Oral Jan. 9, 2020 In Use
72064-0130-30 72064-0130 avapritinib Ayvakit 300.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor PDGFR, KIT, CSFR1 Oral Jan. 9, 2020 In Use
72064-0150-30 72064-0150 avapritinib Ayvakit 50.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor PDGFR, KIT, CSFR1 Oral Jan. 9, 2020 In Use
00002-7190-01 00002-7190 Olaratumab Lartruvo 10.0 mg/mL Immunotherapy Monoclonal Antibody PDGFR Intravenous Feb. 14, 2017 Nov. 27, 2020 No Longer Used
00002-8926-01 00002-8926 Olaratumab Lartruvo 10.0 mg/mL Immunotherapy Monoclonal Antibody PDGFR Intravenous Oct. 19, 2016 Nov. 27, 2020 No Longer Used
00378-6868-01 00378-6868 Anagrelide Hydrochloride Anagrelide Hydrochloride Ancillary Therapy Platelet-Reducing Agent PDE-3 Inhibitor Oral Feb. 28, 2011 Oct. 29, 2010 No Longer Used
00378-6868-05 00378-6868 Anagrelide Hydrochloride Anagrelide Hydrochloride Ancillary Therapy Platelet-Reducing Agent PDE-3 Inhibitor Oral Feb. 28, 2011 Jan. 31, 2014 No Longer Used
00378-6869-01 00378-6869 Anagrelide Hydrochloride Anagrelide Hydrochloride Ancillary Therapy Platelet-Reducing Agent PDE-3 Inhibitor Oral Feb. 28, 2011 March 4, 2011 No Longer Used
00378-6869-05 00378-6869 Anagrelide Hydrochloride Anagrelide Hydrochloride Ancillary Therapy Platelet-Reducing Agent PDE-3 Inhibitor Oral Feb. 28, 2011 Jan. 31, 2014 No Longer Used
54092-0064-01 54092-0064 Anagrelide Agrylin Ancillary Therapy Platelet-Reducing Agent PDE-3 Inhibitor Oral March 14, 1997 March 31, 2008 No Longer Used
54868-5385-00 54868-5385 Anagrelide Anagrelide Ancillary Therapy Platelet-Reducing Agent PDE-3 Inhibitor Oral Aug. 15, 2005 June 30, 2011 No Longer Used
54868-5385-01 54868-5385 Anagrelide Anagrelide Ancillary Therapy Platelet-Reducing Agent PDE-3 Inhibitor Oral Aug. 15, 2005 June 30, 2011 No Longer Used
00185-0155-01 00185-0155 Anagrelide Hydrochloride Anagrelide Hydrochloride Ancillary Therapy Platelet-Reducing Agent PDE-3 Inhibitor Oral April 18, 2005 March 31, 2012 No Longer Used
00185-0155-05 00185-0155 Anagrelide Hydrochloride Anagrelide Hydrochloride Ancillary Therapy Platelet-Reducing Agent PDE-3 Inhibitor Oral April 18, 2005 March 31, 2012 No Longer Used
00185-0156-01 00185-0156 Anagrelide Hydrochloride Anagrelide Hydrochloride Ancillary Therapy Platelet-Reducing Agent PDE-3 Inhibitor Oral April 18, 2005 March 31, 2012 No Longer Used
00185-0156-05 00185-0156 Anagrelide Hydrochloride Anagrelide Hydrochloride Ancillary Therapy Platelet-Reducing Agent PDE-3 Inhibitor Oral April 18, 2005 March 31, 2012 No Longer Used
00172-5240-60 00172-5240 Anagrelide Hydrochloride Anagrelide Hydrochloride 1.0 mg/1 Ancillary Therapy Platelet-Reducing Agent PDE-3 Inhibitor Oral April 18, 2005 In Use
00172-5240-70 00172-5240 Anagrelide Hydrochloride Anagrelide Hydrochloride 1.0 mg/1 Ancillary Therapy Platelet-Reducing Agent PDE-3 Inhibitor Oral April 18, 2005 June 9, 2009 In Use
00172-5241-60 00172-5241 Anagrelide Hydrochloride Anagrelide Hydrochloride 0.5 mg/1 Ancillary Therapy Platelet-Reducing Agent PDE-3 Inhibitor Oral April 18, 2005 In Use
00172-5241-70 00172-5241 Anagrelide Hydrochloride Anagrelide Hydrochloride 0.5 mg/1 Ancillary Therapy Platelet-Reducing Agent PDE-3 Inhibitor Oral April 18, 2005 June 9, 2009 In Use
54092-0063-01 54092-0063 Anagrelide hydrochloride Agrylin 0.5 mg/1, 0.5 mg/1 Ancillary Therapy Platelet-Reducing Agent PDE-3 Inhibitor Oral March 14, 1997 In Use
54868-5443-02 54868-5443 Anagrelide Hydrochloride Anagrelide Hydrochloride 0.5 mg/1 Ancillary Therapy Platelet-Reducing Agent PDE-3 Inhibitor Oral July 19, 2007 In Use
68151-2959-06 68151-2959 Anagrelide Hydrochloride Anagrelide Hydrochloride 0.5 mg/1 Ancillary Therapy Platelet-Reducing Agent PDE-3 Inhibitor Oral April 18, 2005 In Use
69189-5241-01 69189-5241 Anagrelide Hydrochloride Anagrelide Hydrochloride 0.5 mg/1 Ancillary Therapy Platelet-Reducing Agent PDE-3 Inhibitor Oral July 15, 2015 May 24, 2017 No Longer Used
13668-0453-01 13668-0453 Anagrelide Anagrelide 0.5 mg/1, 0.5 mg/1 Ancillary Therapy Platelet-Reducing Agent PDE-3 Inhibitor Oral June 30, 2017 In Use
13668-0453-30 13668-0453 Anagrelide Anagrelide 0.5 mg/1, 0.5 mg/1 Ancillary Therapy Platelet-Reducing Agent PDE-3 Inhibitor Oral June 30, 2017 In Use
13668-0453-74 13668-0453 Anagrelide Anagrelide 0.5 mg/1, 0.5 mg/1 Ancillary Therapy Platelet-Reducing Agent PDE-3 Inhibitor Oral June 30, 2017 In Use
13668-0462-01 13668-0462 Anagrelide Anagrelide 1.0 mg/1, 1.0 mg/1 Ancillary Therapy Platelet-Reducing Agent PDE-3 Inhibitor Oral June 30, 2017 In Use
13668-0462-30 13668-0462 Anagrelide Anagrelide 1.0 mg/1, 1.0 mg/1 Ancillary Therapy Platelet-Reducing Agent PDE-3 Inhibitor Oral June 30, 2017 In Use
13668-0462-74 13668-0462 Anagrelide Anagrelide 1.0 mg/1, 1.0 mg/1 Ancillary Therapy Platelet-Reducing Agent PDE-3 Inhibitor Oral June 30, 2017 In Use
44087-3535-01 44087-3535 Avelumab Bavencio 20.0 mg/mL Immunotherapy Checkpoint Inhibitor PD-L1 Intravenous March 23, 2017 In Use
00310-4500-12 00310-4500 Durvalumab Imfinzi 120.0 mg/2.4mL Immunotherapy Checkpoint Inhibitor PD-L1 Intravenous May 1, 2017 In Use
00310-4611-50 00310-4611 Durvalumab Imfinzi 500.0 mg/10mL Immunotherapy Checkpoint Inhibitor PD-L1 Intravenous May 1, 2017 In Use
50242-0917-01 50242-0917 Atezolizumab Tecentriq 1200.0 mg/20mL Immunotherapy Checkpoint Inhibitor PD-L1 Intravenous May 18, 2016 In Use
50242-0917-86 50242-0917 Atezolizumab Tecentriq 1200.0 mg/20mL Immunotherapy Checkpoint Inhibitor PD-L1 Intravenous Aug. 11, 2016 In Use
50242-0918-01 50242-0918 Atezolizumab TECENTRIQ 840.0 mg/14mL Immunotherapy Checkpoint Inhibitor PD-L1 Intravenous March 8, 2019 In Use
50242-0918-86 50242-0918 Atezolizumab TECENTRIQ 840.0 mg/14mL Immunotherapy Checkpoint Inhibitor PD-L1 Intravenous March 8, 2019 March 18, 2019 In Use
00003-7125-11 00003-7125 nivolumab and relatlimab-rmbw OPDUALAG 12.0 mg/mL, 4.0 mg/mL Immunotherapy Checkpoint Inhibitor, Monoclonal Antibody PD-1, LAG3 Intravenous March 18, 2022 In Use
00006-3029-02 00006-3029 Pembrolizumab Keytruda 50.0 mg/2mL Immunotherapy Checkpoint Inhibitor PD-1 Intravenous Sept. 4, 2014 Dec. 21, 2015 In Use
00003-3756-14 00003-3756 nivolumab OPDIVO 10.0 mg/mL Immunotherapy Checkpoint Inhibitor PD-1 Intravenous Aug. 30, 2021 In Use
00006-3026-02 00006-3026 Pembrolizumab Keytruda 25.0 mg/mL Immunotherapy Checkpoint Inhibitor PD-1 Intravenous Jan. 15, 2015 In Use
00006-3026-04 00006-3026 Pembrolizumab Keytruda 25.0 mg/mL Immunotherapy Checkpoint Inhibitor PD-1 Intravenous Aug. 1, 2019 In Use
61755-0008-01 61755-0008 cemiplimab-rwlc LIBTAYO 50.0 mg/mL Immunotherapy Checkpoint Inhibitor PD-1 Intravenous Sept. 28, 2018 In Use
00003-3772-11 00003-3772 Nivolumab Opdivo 10.0 mg/mL Immunotherapy Checkpoint Inhibitor PD-1 Intravenous Dec. 22, 2014 In Use
00003-3774-12 00003-3774 Nivolumab Opdivo 10.0 mg/mL Immunotherapy Checkpoint Inhibitor PD-1 Intravenous Dec. 22, 2014 In Use
00173-0898-03 00173-0898 dostarlimab Jemperli 50.0 mg/mL Immunotherapy Checkpoint Inhibitor PD-1 Intravenous April 22, 2021 In Use
50881-0006-03 50881-0006 Retifanlimab-dlwr ZYNYZ 25.0 mg/mL Immunotherapy Checkpoint Inhibitor PD-1 Intravenous March 22, 2023 In Use
70114-0340-01 70114-0340 Toripalimab LOQTORZI 240.0 mg/6mL Immunotherapy Checkpoint Inhibitor PD-1 Intravenous Oct. 27, 2023 In Use
00003-3734-13 00003-3734 Nivolumab OPDIVO 10.0 mg/mL Immunotherapy Checkpoint Inhibitor PD-1 Intravenous Dec. 8, 2017 In Use
83718-0000-01 83718-0000 Toripalimab-tpzi LOQTORZI 240.0 mg/6mL Immunotherapy Checkpoint Inhibitor PD-1 Intravenous Oct. 27, 2023 In Use
72579-0121-01 72579-0121 Tislelizumab TEVIMBRA 10.0 mg/mL Immunotherapy Checkpoint Inhibitor PD-1 Intravenous March 14, 2024 In Use
46014-0296-01 46014-0296 talazoparib Talzenna 0.25 mg/1 Chemotherapy Enzyme Inhibitor PARP Oral Oct. 26, 2018 In Use
46014-1195-03 46014-1195 talazoparib Talzenna 1.0 mg/1 Chemotherapy Enzyme Inhibitor PARP Oral Oct. 26, 2018 In Use
00310-0657-58 00310-0657 Olaparib Lynparza 50.0 mg/1 Chemotherapy Enzyme Inhibitor PARP Oral Dec. 24, 2014 March 31, 2020 No Longer Used
63539-0295-30 63539-0295 talazoparib Talzenna 1.0 mg/1 Chemotherapy Enzyme Inhibitor PARP Oral Dec. 10, 2018 In Use
00310-0679-12 00310-0679 Olaparib Lynparza 150.0 mg/1 Chemotherapy Enzyme Inhibitor PARP Oral Aug. 17, 2017 In Use
00310-0679-60 00310-0679 Olaparib Lynparza 150.0 mg/1 Chemotherapy Enzyme Inhibitor PARP Oral Aug. 17, 2017 In Use
00310-0679-95 00310-0679 Olaparib Lynparza 150.0 mg/1 Chemotherapy Enzyme Inhibitor PARP Oral Aug. 31, 2017 In Use
00069-0296-30 00069-0296 talazoparib Talzenna 0.25 mg/1 Chemotherapy Enzyme Inhibitor PARP Oral Oct. 26, 2018 In Use
00069-1195-30 00069-1195 talazoparib Talzenna 1.0 mg/1 Chemotherapy Enzyme Inhibitor PARP Oral Oct. 26, 2018 In Use
00069-1501-30 00069-1501 Talazoparib Talzenna 0.5 mg/1 Chemotherapy Enzyme Inhibitor PARP Oral Jan. 31, 2022 In Use
00069-1751-30 00069-1751 Talazoparib Talzenna 0.75 mg/1 Chemotherapy Enzyme Inhibitor PARP Oral Jan. 31, 2022 In Use
00310-0668-12 00310-0668 Olaparib Lynparza 100.0 mg/1 Chemotherapy Enzyme Inhibitor PARP Oral Aug. 17, 2017 In Use
00310-0668-60 00310-0668 Olaparib Lynparza 100.0 mg/1 Chemotherapy Enzyme Inhibitor PARP Oral Aug. 17, 2017 In Use
00310-0668-95 00310-0668 Olaparib Lynparza 100.0 mg/1 Chemotherapy Enzyme Inhibitor PARP Oral Sept. 1, 2022 In Use
00069-1031-30 00069-1031 Talazoparib Talzenna 0.1 mg/1 Chemotherapy Enzyme Inhibitor PARP Oral June 21, 2023 In Use
00069-1235-30 00069-1235 Talazoparib Talzenna 0.35 mg/1 Chemotherapy Enzyme Inhibitor PARP Oral June 21, 2023 In Use
00173-0909-13 00173-0909 Niraparib ZEJULA 100.0 mg/1 Chemotherapy Enzyme Inhibitor PARP Oral June 27, 2023 In Use
00173-0912-13 00173-0912 Niraparib ZEJULA 200.0 mg/1 Chemotherapy Enzyme Inhibitor PARP Oral June 27, 2023 In Use
00173-0912-61 00173-0912 Niraparib ZEJULA 200.0 mg/1 Chemotherapy Enzyme Inhibitor PARP Oral June 27, 2023 In Use
00173-0915-13 00173-0915 Niraparib ZEJULA 300.0 mg/1 Chemotherapy Enzyme Inhibitor PARP Oral June 27, 2023 In Use
00173-0915-61 00173-0915 Niraparib ZEJULA 300.0 mg/1 Chemotherapy Enzyme Inhibitor PARP Oral June 27, 2023 In Use
63539-0051-30 63539-0051 Talazoparib Talzenna 0.5 mg/1 Chemotherapy Enzyme Inhibitor PARP Oral June 21, 2023 In Use
69656-0103-30 69656-0103 Niraparib Zejula 100.0 mg/1 Chemotherapy Enzyme Inhibitor PARP Oral July 1, 2018 Aug. 31, 2024 In Use
69656-0103-61 69656-0103 Niraparib Zejula 100.0 mg/1 Chemotherapy Enzyme Inhibitor PARP Oral July 1, 2020 Aug. 31, 2024 In Use
69656-0103-90 69656-0103 Niraparib Zejula 100.0 mg/1 Chemotherapy Enzyme Inhibitor PARP Oral March 27, 2017 May 31, 2022 In Use
69660-0201-91 69660-0201 Rucaparib Rubraca 200.0 mg/1 Chemotherapy Enzyme Inhibitor PARP Oral Dec. 19, 2016 Dec. 31, 2025 In Use
69660-0202-91 69660-0202 Rucaparib Rubraca 250.0 mg/1 Chemotherapy Enzyme Inhibitor PARP Oral May 1, 2017 July 31, 2025 In Use
69660-0203-91 69660-0203 Rucaparib Rubraca 300.0 mg/1 Chemotherapy Enzyme Inhibitor PARP Oral Dec. 19, 2016 July 31, 2025 In Use
55513-0078-01 55513-0078 Talimogene Laherparepvec Imlygic 1000000.0 [PFU]/mL Immunotherapy Therapeutic Cancer Vaccine Oncolytic Virus Intralesional Nov. 2, 2015 In Use

Found 10,000 results in 6 milliseconds — Export these results